MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity

Elisa Giovannetti\textsuperscript{1,2}, Niccola Funel\textsuperscript{3}, Godefridus J. Peters\textsuperscript{1}, Marco Del Chiaro\textsuperscript{3}, Leyla A. Erozenci\textsuperscript{1}, Enrico Vasile\textsuperscript{4}, Letizia G. Leon\textsuperscript{1}, Luca E. Pollina\textsuperscript{3}, Annemiek Groen\textsuperscript{1}, Alfredo Falcone\textsuperscript{4}, Romano Danesi\textsuperscript{2}, Daniela Campani\textsuperscript{3}, Henk M. Verheul\textsuperscript{1}, and Ugo Boggi\textsuperscript{3}

Abstract

MicroRNA-21 (miR-21) was reported to be overexpressed and contributes to invasion and gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to evaluate whether miR-21 expression was associated with the overall survival (OS) of PDAC patients treated with gemcitabine and to provide mechanistic insights for new therapeutic targets. miR-21 expression was evaluated in cells (including 7 PDAC cell lines, 7 primary cultures, fibroblasts, and a normal pancreatic ductal cell line) and tissues (neoplastic specimens from 81 PDAC patients and normal ductal samples) isolated by laser microdissection. The role of miR-21 on the pharmacologic effects of gemcitabine was studied with a specific miR-21 precursor (pre-miR-21). Patients with high miR-21 expression had a significantly shorter OS both in the metastatic and in the adjuvant setting. Multivariate analysis confirmed the prognostic significance of miR-21. miR-21 expression in primary cultures correlated with expression in their respective tissues and with gemcitabine resistance. Pre-miR-21 transfection significantly decreased antiproliferative effects and apoptosis induction by gemcitabine, whereas matrix metalloproteinase (MMP)-2/MMP-9 and vascular endothelial growth factor expression were upregulated. Addition of inhibitors of phosphoinositide 3-kinase and mammalian target of rapamycin resulted in decrease of phospho-Akt and prevented pre-miR-21–induced resistance to the proapoptotic effects of gemcitabine. miR-21 expression correlated with outcome in PDAC patients treated with gemcitabine. Modulation of apoptosis, Akt phosphorylation, and expression of genes involved in invasive behavior may contribute to the role of miR-21 in gemcitabine chemoresistance and to the rational development of new targeted combinations. Cancer Res; 70(11): 4528–38. ©2010 AACR.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death, with only 3% of patients alive 5 years after diagnosis (1). The main reasons for this grim prognosis include early metastatic spread, high local recurrence rate, and multifactorial resistance to treatments (2).

In 85% of patients, PDAC is detected at advanced stages, characterized by infiltration of proximal lymph nodes and vascular structures, as well as metastasis to liver/peritoneum. The first-line agent gemcitabine produced some clinical benefit in the advanced setting but yields a limited disease control, with <15% of patients progression-free at 6 months from diagnosis (2, 3). Although several attempts have been made to increase the survival using combinations of chemotherapy and targeted therapy, only a marginal success was achieved with gemcitabine combined with capcetabine or erlotinib, and with a four-drug regimen (4–6). According to the results of CONKO-001 and ESPAC-3 trials (7, 8), gemcitabine also increased the disease-free survival (DFS) and overall survival (OS) in the adjuvant setting. However, the most effective adjuvant chemotherapy remains unclear, and the 5-year survival in patients undergoing resection still hovers between 10% and 20% (1).

Therefore, the identification of predictive factors for gemcitabine activity seems to be critical for maximizing therapeutic efficacy and minimizing useless treatment in PDAC. Pharmacogenetic studies showed correlations of polymorphisms or expression of DNA repair enzymes and nucleoside transporters with outcome in gemcitabine-treated patients (9, 10). However, prognosis of patients harboring favorable genotypes or expression levels for these candidate biomarkers...
is still poor and novel prognostic and therapeutic approaches are warranted.

Global genomic analysis showed that PDAC resulted from aberrations of genes that function through a relatively small number of core signaling pathways (11). In addition to yielding insights into pathogenesis, such studies suggest that the best hope for the development of agents targeting nodal points in the altered pathways lies in the study of mechanisms involved in gene expression regulation.

Recently, microRNAs (miRNA) have emerged as a critical class of negative regulators of gene expression through modulation of posttranscriptional activity of multiple target mRNAs by repression of translation or direct cleavage (12). The role of miRNAs in control of proliferation, differentiation, and apoptosis; the location of several miRNA genes at sites of translocation breakpoints or deletions; and their aberrant expression in many tumors indicated that they can function as tumor suppressors and oncogenes (13). Furthermore, selected miRNAs may influence response to chemotherapy (14–16).

Expression profiling identified several miRNAs aberrantly expressed in PDAC, including four miRNAs differentially expressed in other tumors: miR-155, miR-21, miR-221 and miR-222 (17). These results were corroborated by other studies, showing that miR-21 was among the top miRNAs with increased expression in PDAC (18–20).

miR-21 has been associated with ovarian cancer carcinogenesis (21), and a pivotal role in cancer is suggested by its widespread deregulation in various solid tumors, such as glioblastoma, cholangiocarcinoma, papillary thyroid, breast, esophageal, gastric, hepatocellular, colon, prostate, lung, head and neck, and cervical cancer, as well as in hematologic malignancies (22). The oncogenic properties of miR-21 are further supported by functional studies showing that inhibition of miR-21 expression reduced proliferation of several cancer cells, including breast, hepatocellular, and PDAC cells (23–25), and generated a proapoptotic response in different cell lines, including glioblastoma, cholangiocarcinoma, and PDAC cells (22, 26, 27). In contrast, transfection with miR-21 precursors stimulated invasion, extravasation, and metastasis in in vivo models of glioma, colorectal, and breast cancer (28–30), as well as in cellular models of PDAC (25).

These data suggested that elevated levels of miR-21 might be associated with tumor progression, and because miR-21 is one of the most abundant and easily detectable miRNAs (31), several studies evaluated its role as a prognostic biomarker. The expression of miR-21 has been correlated with clinical stage, lymph node, and distant metastasis as well as with poor prognosis in glioma, colon, breast, and tongue squamous cell cancers (24, 28, 32–34). High miR-21 expression was associated with more aggressive pancreatic endocrine tumors, characterized by increased Ki67 proliferation index and liver metastasis (35). Furthermore, miR-21 expression was significantly lower in the eight PDAC that clustered with the benign pancreas specimens in the study performed by Bloomston and colleagues (18). In situ hybridization showed that miR-21 overexpression was strictly localized to PDAC cells and predictive of shorter survival in node-negative patients, but this subset of patients was small and no data were available on treatment (36). In contrast, no correlation between miR-21 and clinicopathologic findings was observed using PCR on bulk tissues from 25 PDAC patients, without information on chemotherapy (25). Therefore, further studies on a larger number of better-characterized PDAC patients, using techniques to minimize contamination by surrounding stroma, such as laser microdissection (LMD), are warranted.

Recent studies also reported significant correlations between miR-21 expression and resistance to anticancer agents (15, 23, 37). In particular, inhibition of miR-21 increased sensitivity to gemcitabine in cholangiocarcinoma and PDAC cells (25–27). However, miR-21 did not affect gemcitabine-induced apoptosis in colon cancer cells (38), whereas other miRNAs, such as miR-200 and let-7, were involved in the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant PDAC cells (39).

The aim of the present study was to characterize miR-21 expression in a wide repository of PDAC tissues and cells, associated with clinical outcome and gemcitabine activity. We observed a significant correlation between outcome and miR-21 expression in laser-microdissected tumors from gemcitabine-treated patients, both in the metastatic and in the adjuvant setting, as well as a correlation with chemosensitivity in PDAC cells. Further, we characterized several factors, including modulation of apoptosis, Akt phosphorylation, and expression of PTEN and genes involved in invasive behavior, which may contribute to miR-21 role in gemcitabine chemoresistance and provide mechanistic insights for the rational development of new targeted combinations against PDAC.

Materials and Methods

Clinical study

Patients. From December 2001 to October 2004, a total of 81 patients affected by metastatic (n = 31) or nonmetastatic (n = 50) PDAC (median age, 63; range, 32–83) and treated with gemcitabine were enrolled in a retrospective study on determinants of gemcitabine activity (10). Treatment details are in Supplementary Materials and Methods.

Tissues. RNA was extracted from biopsies and primary tumors, resected before chemotherapy, using the LMD7000 instrument (Leica Microsystems), as described previously (40). LMD was also used to obtain cells of epithelium ducts from 5 normal pancreatic tissues, obtained from the “Organ Donor Program,” whereas in 10 cases RNA was extracted from the whole tumor without microdissection. All specimens were obtained according to a protocol approved by the Local Ethics Committee.

Reverse transcription and quantitative PCR analysis of miR-21. RNA (10–100 ng) was reverse transcribed and the resulting cDNA was amplified using the specific Taqman MicroRNA assays (Applied Biosystems) for miR-21 and RNU43 (assay ID, 000397 and 001095, respectively). The PCRs were performed in the 7500HT sequence detection system (Applied Biosystems), in accordance with the manufacturer’s instructions. Specimens were amplified in triplicate with appropriate nontemplate controls. Amplification data were
normalized to RNU43 expression. Quantification of relative expression [reported as arbitrary units (a.u.)] was performed using the \( \Delta C_t \) method. Quantitative PCR data showed a variability coefficient of \( C_t \) always lower than 2% of mean values.

**In vitro studies**

**Cells and cytotoxicity studies.** Seven PDAC cell lines, the human pancreatic duct epithelial-like cell line hTERT-HPNE, and skin fibroblasts Hs27 were obtained from the American Type Culture Collection, whereas seven primary PDAC cultures (LPc006, LPc028, LPc033, LPc067, LPc111, LPc167, and PP437) were isolated from patients at Pisa Hospital (40). The cell growth–inhibitory effect of 72-hour gemcitabine exposure was studied as described previously (10).

**Quantitative PCR analysis of miR-21.** RNA was extracted according to the Trizol-chloroform protocol, and the miR-21 basal expression as well as its modulation after gemcitabine treatment using IC50 concentrations were assessed by quantitative PCR, as described above. Data were normalized to RNU-43, and quantification of miR-21 expression compared with untreated controls was assessed using the \( \Delta \Delta C_t \) method (10).

**miR-21 transfection.** The effect of miR-21 on chemosensitivity and apoptosis was evaluated by transfecting the PDAC cells with pre-miR-21 precursors (pre-miR-21) or antisense oligonucleotides (anti-miR-21) purchased from Ambion (assay ID, PM10206 and AM10206, respectively) at 30 nmol/L final concentration. Cells were plated at 200,000 per well in 3 mL RPMI 1640 with 10% fetal bovine serum (FBS) and 1% antibiotics. After 24 hours, cells were exposed to 9 μL Oligofectamine (Invitrogen) in serum-free medium and mixed for 10 minutes, followed by addition of 3 μL miR-21 precursor/inhibitor. Cells were also incubated with miRNA-negative controls and FAM-labeled pre-miR/anti-miR (Ambion). After 24 hours, the medium was replaced with RPMI 1640 with 10% FBS, without antibiotics. To evaluate the effects on cell growth, cells were allowed to grow for additional 48 or 72 hours in drug-free medium or treated with gemcitabine, as described previously (10, 40). To evaluate apoptosis induction...
and modulation of cell signaling and invasion, cells were allowed to grow for additional 48 hours in drug-free medium or treated with 50 μmol/L gemcitabine, 10 μmol/L LY294002, and 200 nmol/L rapamycin, alone and in combinations (26), as described in Supplementary Materials and Methods. Additional control wells were used for RNA extraction, as described above, whereas the transfection efficiency with FAM-labeled pre-miR/anti-miR controls was evaluated with fluorescence microscopy.

Statistics. All experiments were performed in triplicate and repeated thrice. Data were expressed as mean ± SE and analyzed by Student’s t test or ANOVA followed by the Tukey’s multiple comparison. Comparison of clinical information and miR-21 expression was made using Pearson χ² test and Wilcoxon test. The relationship between miR-21 expression and outcome was evaluated by stratifying the patients with respect to the median expression value.

OS was calculated from the date of pathologic diagnosis (i.e., the date of surgery/biopsy) to the date of death, DFS was defined as the time from the date of diagnosis to the date of first relapse or death in radically resected patients, and progression-free survival (PFS) was defined as the time from the date of diagnosis to the date of progression or death in metastatic patients. OS, PFS, and DFS curves were constructed using Kaplan-Meier method, and differences were analyzed using log-rank test. The significant prognostic variables of OS in univariate analysis were included in multivariate analyses using Cox’s proportional hazards model. Data were analyzed using SPSS v.17 statistical software (SPSS, Inc.). Statistical significance was set at P < 0.05.

Results

Clinical study

miR-21 expression in pancreatic specimens. LMD was performed on 81 samples from PDAC patients, including 7 tumor specimens from which primary cultures were derived. LMD was also performed on five specimens from normal ducts. For each sample, the precision of the focus of the laser beam allowed to pick up 5,000 cells, with high degree of accuracy and extremely low risk of contamination (Fig. 1A, video). miR-21 was detectable in all samples, and Fig. 1A shows its large variability across the tissues, with median value of 0.315 a.u. (range, 0.003–18.336). Remarkably, miR-21 expression profile differed significantly between grade 1/2 (n = 33) and grade 3 (n = 35) tumors (P = 0.01, Wilcoxon rank sum test). In contrast, no difference was detected in miR-21 expression levels according to stage or other clinicopathologic parameters (Table 1).

The mean miR-21 expression of normal pancreatic duct samples was ∼1,000-fold lower than the levels in microdissected tumors (Fig. 1A). Furthermore, the nonmicrodissected tumor tissues had a significantly lower expression of miR-21 than their respective microdissected samples (P = 0.01; Fig. 1A).

miR-21 overexpression correlated with worse outcome in PDAC patients treated with gemcitabine. Clinical data were available from 31 patients in the metastatic and 28 in the adjuvant setting, followed-up until December 31, 2009, with follow-up ranging from 1.6 to 60.5 months (median, 17.3 mo). Response data are in Supplementary Table S1.

Table 2 summarizes the clinicopathologic characteristics and their relation with outcome in metastatic patients. The median PFS and OS were 5.5 and 8.4 months, respectively. The high miR-21 expression group had a poorer prognosis than the low expression group. Patients with miR-21 expression above median had a significantly shorter median OS [6.7; 95% confidence interval (95% CI), 5.5–7.9 mo] compared with patients with miR-21 expression lower than median [11.2; 95% CI, 4.5–17.8 mo; hazard ratio (HR), 3.1; 95% CI, 1.4–7.1; P = 0.01]. Similar results were obtained with the PFS curves of patients with miR-21 expression above median, with a median of 4.2, compared with 7.8 months in patients with the lowest miR-21 expression (HR, 2.4; 95% CI, 1.1–5.3;
miR-21 is expressed in all PDAC cells and significantly increased after gemcitabine treatment. The expression of miR-21 was detectable in all PDAC cell lines/cultures as well as in hTERT-HPNE cells and Hs27 fibroblasts. However, this expression differed among cells, ranging from 4.5 a.u. in PL45 to 0.1 a.u. in Hs27 cells (Fig. 2A). miR-21 expression levels in primary cultures were correlated to the expression detected in their respective tissues (Supplementary Fig. S1).

Although the small sample size of cells used in this study precluded the assessment of the predictive value of miR-21 expression data as validated determinants of chemosensitivity, the Spearman test showed a trend toward significant correlation ($P = 0.08$) between the miR-21 expression and gemcitabine $IC_{50}$ (Fig. 2B). Furthermore, cells with miR-21 expression below the median had significantly lower $IC_{50}$s than cells with miR-21 expression above the median (Fig. 2C).

To evaluate whether gemcitabine affects miR-21 expression in vitro, we measured the levels of miR-21 in 13 PDAC cells/cultures after 72-hour exposure to gemcitabine at $IC_{50}$. This treatment resulted in a significant increase of miR-21 expression, ranging from 2.1- to 19.1-fold, in comparison with basal expression (Fig. 2D).

### miR-21 inhibits gemcitabine antiproliferative effects and apoptosis induction in PDAC cells

To explore the role of miR-21 on antiproliferative effects and apoptosis induction after gemcitabine, relatively sensitive (LPc028 and LPc067) and resistant (LPc111 and LPc006) cells were transfected with miR-21–specific inhibitor and precursor. Transfection efficiency was evaluated by analysis of fluorescent microscope images of cells transfected with specific FAM-labeled pre-miR/anti-miR. These tests showed at least 60% efficiency for both transfection conditions in each cell type, with >70% cell viability. Furthermore, we studied miR-21 expression by quantitative PCR in three of the four transfected cultures.
showing a 3-, 2-, and 1.8-fold increase of miR-21 expression in LPc067, LPc111, and LPc028 cells, respectively (Supplementary Fig. S2). The increased expression of miR-21 was associated with ∼15% increased proliferation and reduced apoptosis in cells transfected with pre-miR-21, suggesting that aberrant expression of this miRNA enhanced cell growth.

Transfection with pre-miR-21 resulted in significant reduction of gemcitabine antiproliferative effects, with increase of 72-hour exposure to gemcitabine at IC_{50} from 1.3 ± 0.3 nmol/L (LPc028), 7.2 ± 0.6 nmol/L (LPc006), 5.5 ± 0.9 nmol/L (LPc067), and 16.6 ± 2.0 nmol/L (LPc111) to 15.6 ± 2.2, 44.5 ± 3.1, 37.6 ± 4.2, and 85.1 ± 11.4 nmol/L, respectively (Fig. 3A).

The effects on apoptosis induction by gemcitabine were studied on LPc028 and LPc067 cells, which were relatively sensitive to gemcitabine antiproliferative effects but characterized by miR-21 expression above and below the median, respectively. The different assays allowed the evaluation of early apoptosis, late apoptosis, and global cell death, showing similar results (Supplementary Fig. S3). Both cultures showed decreased gemcitabine-induced apoptosis when transfected with pre-miR-21. In LPc067 cells, early apoptosis was reduced from 38% to 23%, whereas late apoptosis was reduced from 8% to 5%, as detected by Annexin V assay. In contrast, LPc067 cells transfected with anti-miR-21 had increased cell death, and analysis of typical apoptotic morphology showed ∼10% increased apoptotic index in gemcitabine-treated cells. Similarly, only 12% of LPc028 underwent apoptosis after gemcitabine treatment in cells transfected with pre-miR-21, whereas a higher percentage (28%) was found after gemcitabine

| Table 3. Survival according to clinical characteristics and miR-21 expression |
|-----------------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic                          | Adjuvant setting |                | Adjuvant + palliative setting |                |                |                |                |                |                |                |                |                |                |                |                |
|                                           | n              | OS, mo (95% CI) | P                | n              | OS, mo (95% CI) | P                | n              | OS, mo (95% CI) | P                | n              | OS, mo (95% CI) | P                | n              | OS, mo (95% CI) | P                |
| No. patients                            | 28             | 16.0 (14.3–17.7) |                | 59             | 12.4 (9.7–15.2) |                |                |                |                |                |                |                |                |                |                |
| Age (median years)                      |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| ≤63                                      | 12             | 16.7 (9.8–23.5) | 0.66             | 34             | 12.3 (8.6–15.9) | 0.97             |                |                |                |                |                |                |                |                |
| >63                                      | 16             | 13.2 (3.5–22.9) | 0.59             | 25             | 12.5 (8.5–16.5) | 0.19             |                |                |                |                |                |                |                |                |
| Sex                                      |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| Male                                     | 13             | 16.0 (13.5–18.5) | 0.59             | 35             | 10.5 (6.0–15.0) | 0.19             |                |                |                |                |                |                |                |                |
| Female                                   | 15             | 16.7 (9.3–24.0) | 0.39             | 24             | 13.1 (10.6–15.5) |                |                |                |                |                |                |                |                |                |
| Clinical stage                           |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| I–II                                    | 19             | 15.5 (10.3–20.8) | 0.77             | 19             | 15.5 (10.3–20.8) | 0.05             |                |                |                |                |                |                |                |                |
| III–IV                                  | 8              | 19.0 (14.5–23.5) | 0.77             | 39             | 10.5 (5.8–15.3) | 0.05             |                |                |                |                |                |                |                |                |
| Lymph node                              |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| Negative                                 | 2              | 6.4             | 0.71             | 2              | 6.4             | 0.71             |                |                |                |                |                |                |                |                |
| Positive                                 | 25             | 16.7 (14.5–18.8) |                | 25             | 16.7 (14.5–18.8) |                |                |                |                |                |                |                |                |                |
| Vascular infiltration                    |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| No                                       | 19             | 16.0 (12.0–20.0) | 0.93             | 19             | 16.0 (12.0–20.0) | 0.93             |                |                |                |                |                |                |                |                |
| Yes                                      | 9              | 19.0 (12.2–25.8) |                | 9              | 19.0 (12.2–25.8) |                |                |                |                |                |                |                |                |                |
| Neural infiltration                      |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| No                                       | 22             | 16.7 (12.7–20.6) | 0.70             | 22             | 16.7 (12.7–20.6) | 0.70             |                |                |                |                |                |                |                |                |
| Yes                                      | 6              | 13.2 (2.2–24.2) | 0.71             | 6              | 13.2 (2.2–24.2) | 0.71             |                |                |                |                |                |                |                |                |
| PanIN                                    |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| No                                       | 9              | 16.7 (14.7–18.6) | 0.71             | 9              | 16.7 (14.7–18.6) | 0.71             |                |                |                |                |                |                |                |                |
| Yes                                      | 19             | 16.0 (13.0–19.0) |                | 19             | 16.0 (13.0–19.0) |                |                |                |                |                |                |                |                |                |
| Grading                                  |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| 1–2                                     | 12             | 19.5 (11.9–27.1) | 0.13             | 18             | 16.7 (14.0–19.4) | 0.12             |                |                |                |                |                |                |                |                |
| 3                                        | 15             | 14.7 (10.1–19.4) |                | 18             | 12.3 (9.7–14.9) |                |                |                |                |                |                |                |                |                |
| Setting                                  |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| Metastatic                               |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| Adjuvant                                 |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| miR-21 expression                        |                |                |                  |                |                |                  |                |                |                |                |                |                |                |                |
| ≤Median                                  | 12             | 23.7 (12.3–35.0) | 0.008            | 26             | 16.2 (13.3–19.2) | 0.003            |                |                |                |                |                |                |                |                |
| >Median                                  | 16             | 13.2 (8.3–18.0) |                | 33             | 8.8 (5.6–11.8) |                |                |                |                |                |                |                |                |                |

NOTE: Data on age, sex, treatment, and miR-21 were available from all; on stage from 27 of 28 patients in the adjuvant and from all in the metastatic setting; on grading from 27 of 28 patients in the adjuvant and from 9 of 31 patients in the metastatic setting; on lymph node infiltration from 27 of 28 patients in the adjuvant setting; and on vascular/neural infiltration and pancreatic intraepithelial neoplasia from the 28 patients in the adjuvant setting.
exposure in cells treated with miRNA control (Fig. 3B). Gemcitabine exposure in cells transfected with anti-miR-21 significantly increased apoptotic index up to 39%.

To further investigate the effects of miR-21 on pathways involved in inhibition of apoptosis, cells were transfected with pre-miR-21 and treated with gemcitabine and agents targeting Akt/protein kinase B/mammalian target of rapamycin (mTOR) pathway, such as LY294002 and rapamycin. The apoptotic index after LY294002 or rapamycin treatment was <8% in both cell cultures. These values were reduced around 3% to 5% in cells transfected with pre-miR-21. The combination of gemcitabine with rapamycin slightly increased the apoptotic index in both cell cultures, whereas the combination of gemcitabine with LY294002 resulted in an additive effect on apoptosis induction (+6%) only in LPc067 cells. These combinations were not able to reverse the antiapoptotic effect of pre-miR-21 transfection. However, the combination of all the three drugs (i.e., gemcitabine + LY294002 + rapamycin)

Figure 2. A, gemcitabine IC_{50} (black columns) and expression values of miR-21 in PDAC cell lines (gray columns), primary cultures (white columns), hTERT-HPNE cells, and Hs27 fibroblasts. B, correlation between miR-21 expression and gemcitabine cytotoxic activity. C, analysis of median IC_{50} in cells with miR-21 expression above and below the median. D, significant modulation of miR-21 expression in PDAC cells treated with gemcitabine at IC_{50}. Columns, mean from three independent experiments; bars, SE.
miR-21 and Gemcitabine Resistance in Pancreatic Cancer

significantly increased the apoptotic index with respect to gemcitabine alone and reversed the antiapoptotic effect observed in the cells transfected with pre-miR-21. The apoptotic index in LPc067 cells transfected with pre-miR-21 and treated with gemcitabine + LY294002 + rapamycin was 49% ($P < 0.05$ versus 28% of LPc067 cells transfected with pre-miR-21 treated with gemcitabine). Similar results were observed in the LPc028 cells (Fig. 3B).

**miR-21 affects PTEN and Akt expression.** Previous studies showed that (a) miR-21 regulates expression of PTEN and phosphorylation of its downstream kinase Akt (24, 26, 33) and (b) the reduction of phospho-Akt (pAkt) correlated with the enhancement of gemcitabine-induced apoptosis and antitumor activity *in vitro* and *in vivo*, suggesting that Akt pathway plays a significant role in mediating drug resistance in PDAC cells (41). Therefore, we investigated the PTEN expression and Akt phosphorylation status before and after pre-miR-21 transfection and drug treatment.

Pre-miR-21 transfection reduced PTEN expression in all the cell cultures (Fig. 3C), whereas tumors with high miR-21 expression had lower PTEN expression (Supplementary Fig. S4).

Akt phosphorylation was evaluated in two cell cultures, including LPc028, described previously, and LPc006 (relatively resistant to gemcitabine and with high miR-21 expression). Transfection with pre-miR-21 resulted in an increase of pAkt/Akt ratio, ranging from +24% to +63% in LPc006 and
miR-21 enhanced metalloproteinase expression and vascular endothelial growth factor expression/secretion. Because miR-21 has been reported to have proinvasion and proangiogenic effects, we evaluated the expression of possible markers of these activities. As marker for invasion, we investigated mRNA expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 in LPc067 cells transfected with pre-miR-21, showing a 5.6- to 5.9-fold increase (P < 0.05). As marker for angiogenesis, we evaluated both vascular endothelial growth factor (VEGF) mRNA expression levels and VEGF secretion into the medium, showing an increase after miR-21 transfection of +20% and +104% (LPc028) and +56% and +58% (LPc067), respectively (Supplementary Fig. S5).

Discussion

This study evaluated the effect of miR-21 on the outcome of PDAC and, to our knowledge, is the first to show its association with PFS and OS in advanced PDAC patients treated with gemcitabine. Furthermore, we observed a significant association between miR-21 expression and DFS/OS in patients who underwent radical resection and were treated with gemcitabine in the adjuvant setting. Recent trials supported the use of chemotherapy in radically resected patients, but the most effective regimen (gemcitabine or 5-fluorouracil/leucovorin) remains unclear (7, 8). Similarly a phase 3 trial showed that a cisplatin–epirubicin–5-fluorouracil–gemcitabine regimen obtained a 1-year survival rate of 38.5%, which was significantly better than single-agent gemcitabine (6). However, there are still no guidelines for selecting treatment for PDAC both in the adjuvant and in the metastatic setting.

Several molecular predictors of response and toxicity to chemotherapy in PDAC are being investigated, including germ-line markers such as polymorphisms (9), tumor-related molecular markers such as mutations, and aberrations in mRNA/protein expression (11, 42). Over the last few years, miRNA emerged as a prominent class of gene regulators, and their aberrant expression was linked to different tumors, including PDAC (13, 17 18). Several studies suggested their use for diagnostic purpose, showing that expression pattern of 217 miRNAs classified poorly differentiated tumors better than data from 16,000 mRNA (43). However, a miRNA can regulate multiple coding genes related to tumor growth and is also likely to more effectively reflect the status and outcome of a disease.

More than 500 miRNAs are expressed in human cells, but high-throughput screenings identified a limited number of key miRNAs. Since its identification as the miRNA most strongly upregulated in glioblastoma, miR-21 has attracted the attention of researchers in various fields (22). In situ hybridization showed strong miR-21 expression only in PDAC cells but not in the surrounding stroma (36). Interestingly, in the present study, we observed a significant lower expression of miR-21 in 10 tumor samples, which were not obtained by LMD, than in their corresponding laser-microdissected specimens. This suggests that LMD succeed in eliminating the stroma, which can mask the true expression of miR-21. The study of Dillhoff and colleagues (36) also reported that miR-21 overexpression was predictive of shorter survival in node-negative but not in all the patients. However, this subset of patients was small (n = 17), and they had a significantly longer OS than patients with positive lymph nodes. Previous studies reported controversial data about the prognostic role of lymph node and staging, and most PDAC patients have American Joint Committee on Cancer stage >2A at diagnosis (44), as in our population.

Several studies showed that more advanced/malignant tumors expressed higher levels of miR-21 (32–35). However, in gastric carcinomas, in which miR-21 can serve as a diagnostic marker, its levels did not seem to have prognostic value (45), whereas reports in patients with diffuse large B-cell lymphoma suggested that high levels of miR-21 in tumor and serum were associated with better prognosis (46). These controversial data suggested that the prognostic role of miR-21 is possibly tumor specific as well as treatment related. Indeed, miR-21 expression was correlated with resistance to several anticancer agents in different models (15, 23, 26, 37). In particular, inhibition of miR-21 increased sensitivity and apoptosis induction by gemcitabine in PDAC but not in colon cancer cells (25, 38).

The present study revealed that PDAC cells with miR-21 expression below the median had significantly lower gemcitabine IC_{50}s than cells with miR-21 expression above the median. miR-21 expression was similar in PDAC cultures and their respective tissues, as reported in glioblastoma cultures and tumors (22), suggesting the suitability of these ex vivo models for further molecular analysis. However, miR-21 expression was detectable at similar levels in PDAC and hTERT-HPNE cells. These results can be explained by the fact that although hTERT-HPNE cells (47) have a normal phenotype...
miR-21 and Gemcitabine Resistance in Pancreatic Cancer

(diploid, with wild-type p16INK4a, K-Ras, and p53), miR-21 expression may be related to the immortalization of these cells by the ectopic expression of hTERT, as reported previously in the immortalized pancreatic ductal cells HPDE (25).

Of note, miR-21 expression was increased after exposure to gemcitabine in all PDAC cells, suggesting that this miRNA can also contribute to acquired chemoresistance and explain the short time of response/stabilization in most PDAC patients. However, no tissues from previously treated patients were available, and high levels of miR-21 may not only characterize cancers but also represent a common feature of pathologic growth or stress, as observed in models of mouse hypertrophic heart (48).

Further, we studied the activity of miR-21 on pharmacologic effects of gemcitabine and molecular pathways involved in its activity. Increased expression of miR-21 following transfection with a specific precursor led to a significant reduction of antiproliferative effects and apoptotic index in cells treated with gemcitabine, as reported previously (25, 27). Computational algorithms predict hundreds of miRNA as possible targets for miR-21, but only a few of them have been experimentally validated and are involved in apoptosis regulation. Previous studies showed that both miR-21 and anti-miR-21 modulated a luciferase construct containing PTEN 3’ untranslated region and the expression of PTEN in vitro, whereas the staining of PTEN was reversely correlated with miR-21 in tongue squamous cell carcinoma (24, 26, 33).

Other reports did not find changes in PTEN expression after transfection with miR-21 precursors in PDAC cells (25), but in the present study, transfection with pre-miR-21 resulted in reduction of PTEN expression, which was also negatively correlated with miR-21 expression in 14 PDAC samples. Furthermore, in agreement with the hypothesis that overexpression of miR-21 leads to downregulation of PTEN and a more active signaling through the phosphoinositide 3-kinase (PI3K)–Akt pathway, rendering the cancer cells less susceptible to apoptosis, we found that increased miR-21 expression was associated with activation of PI3K/Akt/mTOR pathway. Then, we showed that drugs targeting PI3K/Akt/mTOR pathway reduced pAkt levels and enhanced apoptosis when used in combination with gemcitabine. These findings are consistent with studies showing that addition of PI3K inhibitors to gemcitabine-treated cells decreased pAkt and increased apoptosis (41). In contrast, rapamycin treatment alone resulted in highly increased pAkt levels compared with untreated cells and cells treated with gemcitabine. These results can be explained by the ability of rapamycin to inhibit the mTORC1-mediated pathway through dephosphorylation of several downstream effectors, including S6K1, which acted as antagonist of PI3K/Akt/mTOR pathway (49). Therefore, rapamycin-mediated inhibition of mTORC1 resulted in induction of Akt activity (50). However, the pAkt/Akt ratio was strongly downregulated by the combination of rapamycin with gemcitabine and LY294002, and the combination of the three drugs overcame the resistance to apoptosis caused by pre-miR-21 transfection, yielding useful information on critical targets to reduce chemoresistance.

Another recently identified miR-21 target is RECK, which might mediate miR-21 invasiveness and angiogenesis by inhibiting MMPs (22). Therefore, we studied miRNA expression of MMP-2 and MMP-9, as well as miRNA and protein expression of VEGF, which were positively correlated with miR-21 expression, as reported in other PDAC cells (25).

The consistency and strength of the accumulating preclinical data, together with our clinical data on correlation with outcome, strongly suggest that PDAC cells are more aggressive and resistant to gemcitabine if they have high expression of miR-21, which therefore represents a promising target for prognostic and therapeutic approaches.

About the prognostic use of miR-21, further validation in prospective studies is warranted, and more accessible samples sources, such as miR-21–enriched tumor-derived exosomes from blood, should be investigated. Similarly, the modulation of miR-21 targets seems as a promising adjuvant to current therapies of PDAC in selected patients, thus providing a potential new tool for treatment optimization.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Mauro Baron (Leica Microsystems) for the valuable technical support.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/11/2009; revised 02/22/2010; accepted 03/17/2010; published OnlineFirst 05/11/2010.

References


Correction: Online Publication Dates for Cancer Research April 15, 2010 Articles

The following articles in the April 15, 2010 issue of Cancer Research were published with an online publication date of April 6, 2010 listed, but were actually published online on April 13, 2010:


Dudka AA, Sweet SMM, Heath JK. Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res 2010;70:3391–401. Published OnlineFirst April 13, 2010. doi:10.1158/0008-5472.CAN-09-3033.

MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity


Cancer Res 2010;70:4528-4538. Published OnlineFirst May 11, 2010.